Home Compliance At Large: Why Didn’t Novartis Try to Conceal its Ongoing Bribery? ComplianceFCPANews At Large: Why Didn’t Novartis Try to Conceal its Ongoing Bribery? July 30, 2020 29 Share FacebookLinkedinTwitter Taljat David | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance Money Makes the Compliance Go Around Compliance Core FCPA Beliefs Cyber Maryland Legislature Passes Comprehensive Data Privacy Bill